Breast Imaging

What Imaging Should You Order for Pathologic Nipple Discharge in a Young Transfeminine Patient?

·
What Imaging Should You Order for Pathologic Nipple Discharge in a Young Transfeminine Patient?

A 27-year-old transfeminine patient presents to your clinic with a new concern: for the past two weeks, she has noticed a spontaneous, reddish-brown discharge from her right nipple. She has been on gender-affirming hormone therapy for five years. The physical exam is notable for well-developed breast tissue bilaterally (Tanner stage 4) and expressible serosanguinous discharge from a single duct on the right, without a palpable mass. You recognize these as features of pathologic nipple discharge, and now you must decide on the most appropriate initial imaging study. This clinical workflow article details the American College of Radiology (ACR) recommendations for this specific scenario. For this patient, the ACR designates breast ultrasound as Usually Appropriate.

Who Fits This Clinical Scenario?

This guidance applies to a specific patient population: adult transfeminine (male-to-female) individuals younger than 30 years of age who present with pathologic nipple discharge.

Key inclusion criteria for this workflow are:

  • Patient Identity: Transfeminine (male-to-female).
  • Age: Younger than 30 years.
  • Clinical Presentation: Pathologic nipple discharge. This is typically defined as discharge that is spontaneous, unilateral, persistent, and arises from a single duct. The character of the discharge is also important; bloody (sanguineous), serosanguinous, serous, or clear (watery) discharge is more concerning than milky or multicolored discharge.

It is critical to distinguish this presentation from other, similar scenarios that follow different diagnostic pathways:

  • Physiologic Nipple Discharge: If the discharge is bilateral, non-spontaneous (occurs only with manipulation), and involves multiple ducts, it is likely physiologic. This presentation is managed differently and typically does not require initial imaging.
  • Patients 30 Years or Older: The imaging approach changes for transfeminine patients aged 30 and older, where the baseline risk for malignancy is higher and mammography plays a more central role.
  • Cisgender Patients: While there is overlap, the workup for pathologic nipple discharge in young cisgender women or men follows slightly different ACR variant pathways, reflecting different underlying breast architecture and risk profiles.

What Diagnoses Are You Working Up in This Scenario?

When ordering imaging for pathologic nipple discharge in a young transfeminine patient, the goal is to evaluate the ductal system and surrounding breast tissue for an underlying cause. The differential diagnosis includes several key possibilities.

The most common causes of pathologic nipple discharge are benign. An intraductal papilloma, a small, wart-like growth projecting into a breast duct, is a classic cause of bloody or serosanguinous discharge. Similarly, duct ectasia, a condition where a milk duct widens and its walls thicken, can lead to discharge and is also a benign process. Both are well-visualized with the recommended imaging.

Gender-affirming hormone therapy, particularly estrogen, induces significant glandular and stromal proliferation, similar to female breast development. These hormone-induced proliferative changes can themselves be associated with benign conditions leading to nipple discharge. The developing breast tissue is often dense, which influences the choice of initial imaging.

Although less common in this age group, breast cancer must be considered. The risk of breast cancer in transfeminine individuals on long-term hormone therapy is higher than in cisgender men, though generally lower than in cisgender women. Pathologic nipple discharge is a potential presenting sign of ductal carcinoma in situ (DCIS) or invasive ductal carcinoma. Therefore, any workup must be sufficient to exclude malignancy.

Finally, while less common for serosanguinous discharge, an underlying infection or abscess can sometimes present atypically. Imaging helps differentiate a fluid collection or inflammatory changes from a solid mass or ductal abnormality.

Why Is Breast Ultrasound the Recommended Initial Study?

The ACR Appropriateness Criteria rate breast ultrasound (US) as Usually Appropriate for the initial evaluation of pathologic nipple discharge in a transfeminine patient under 30. This recommendation is based on the modality’s high diagnostic yield, lack of ionizing radiation, and suitability for the expected breast tissue characteristics in this population.

Ultrasound excels at evaluating the retroareolar region and the ductal system. It can directly visualize ductal dilation, identify small intraductal masses like papillomas, characterize lesions as cystic or solid, and guide percutaneous biopsy if a suspicious finding is identified. In younger patients and those on estrogen therapy, breast tissue is typically dense. Ultrasound is less affected by breast density than mammography, often providing a clearer assessment of underlying abnormalities. Furthermore, breast US involves no ionizing radiation (0 mSv), a key consideration in a younger patient who may require future imaging.

Other imaging modalities are also rated for this scenario:

  • Diagnostic Mammography and Digital Breast Tomosynthesis (DBT): These are also rated Usually Appropriate. However, they are often considered secondary to ultrasound in this specific age group. The dense breast tissue common in young, developing breasts can obscure underlying findings on a mammogram, reducing its sensitivity. Mammography and DBT do involve a low dose of ionizing radiation (☢☢ 0.1-1 mSv). They are most valuable as an adjunct to ultrasound, particularly if the ultrasound is suspicious or inconclusive, or to screen the remainder of the breast tissue for calcifications or other findings not visible on ultrasound.
  • Breast MRI without and with IV Contrast: This is rated Usually Not Appropriate as an initial imaging tool for this problem. While highly sensitive, breast MRI has lower specificity and can lead to the detection of incidental, benign findings, potentially triggering unnecessary biopsies and patient anxiety. Its role is reserved for specific circumstances, such as when ultrasound and mammography are negative but clinical suspicion for cancer remains very high, or for pre-operative planning if a malignancy is found.
  • Ductography: This is also rated Usually Not Appropriate. This invasive procedure, which involves cannulating the discharging duct and injecting contrast, has been largely superseded by the excellent, non-invasive visualization offered by high-resolution ultrasound and, when needed, breast MRI.

What’s Next After Breast Ultrasound? Downstream Workflow

The results of the breast ultrasound will guide the subsequent steps in the patient’s care. The workflow typically follows one of several paths, often categorized by the Breast Imaging Reporting and Data System (BI-RADS) assessment.

  • Negative or Benign Finding (BI-RADS 1 or 2): If the ultrasound is entirely normal or shows a clearly benign finding like simple duct ectasia without a suspicious mass, the patient can typically be reassured. The next step is clinical management. If the discharge is minimal and non-bloody, observation may be appropriate. If a bloody discharge persists despite negative imaging, referral to a breast surgeon or specialist for consultation is recommended, as a small percentage of malignancies can be missed on initial imaging.
  • Probably Benign Finding (BI-RADS 3): If the ultrasound identifies a finding that is almost certainly benign but not definitively so (e.g., a complicated cyst or a cluster of microcysts), the standard recommendation is short-term imaging follow-up. This usually involves a repeat ultrasound of the area in 6 months to ensure stability.
  • Suspicious or Highly Suspicious Finding (BI-RADS 4 or 5): If the ultrasound reveals an intraductal mass, a solid nodule with suspicious features, or other concerning abnormalities, the definitive next step is tissue sampling. An ultrasound-guided core needle biopsy is the procedure of choice. It is important to note that while “Image-guided core biopsy” is rated Usually Not Appropriate as an initial imaging test, it becomes the required next step once a suspicious lesion is identified by an appropriate initial test like ultrasound. The results of the biopsy will determine the need for surgical excision and further treatment.

Pitfalls to Avoid (and When to Get Help)

When managing this specific clinical scenario, several potential pitfalls can compromise diagnostic accuracy and patient care.

First, avoid dismissing pathologic discharge as a simple side effect of hormone therapy without a proper imaging workup. While benign hormonal changes are common, malignancy must be excluded. Second, do not default to mammography as the primary initial test in this under-30 age group; the density of the breast tissue makes ultrasound a more sensitive first step. Third, ordering a breast MRI as the first-line study is a common error that can lead to a cascade of unnecessary interventions due to its high rate of false-positive findings. Finally, ensure close correlation between the physical exam finding (the specific discharging duct) and the area interrogated during the ultrasound. If imaging is negative but a highly suspicious discharge persists, escalate care by referring the patient to a breast specialist for further evaluation, which may include consideration of duct excision.

Related ACR Topics and Tools

This article covers one specific variant within the broader topic of nipple discharge. For a comprehensive overview of all related scenarios, from physiologic discharge to presentations in different age groups and patient populations, please see our parent guide.

For additional decision support and technical details, the following GigHz resources are available:

Frequently Asked Questions

Why is the workup for a young transfeminine patient different from a young cisgender male with nipple discharge?

The primary difference is the presence of developed glandular breast tissue in transfeminine patients due to gender-affirming hormone therapy. This tissue is susceptible to conditions like intraductal papillomas and, rarely, breast cancer, similar to cisgender women. The breast tissue is also typically dense, making ultrasound the preferred initial imaging modality. In contrast, a young cisgender male has minimal glandular tissue, and the differential for nipple discharge is narrower, though still requires a careful workup.

Does the duration of hormone therapy change the imaging recommendation?

For the initial imaging choice, the duration of hormone therapy does not change the primary recommendation to start with ultrasound in a patient under 30. However, the duration of therapy is an important part of the clinical history, as longer-term estrogen exposure is a factor in assessing the overall risk for breast cancer, which may influence the level of clinical suspicion and the threshold for biopsy if an indeterminate finding is seen.

If the ultrasound is negative but the pathologic discharge continues, what is the next step?

If a clinically suspicious discharge (e.g., spontaneous, bloody, from a single duct) persists despite a negative ultrasound, the workup is not necessarily complete. The next step is typically a referral to a breast surgeon or specialist. They may recommend a diagnostic mammogram as a complementary study or consider a surgical approach like terminal duct excision for both diagnosis and treatment.

Is mammography ever the first-choice imaging study in this patient group?

While breast ultrasound is generally the preferred initial study, mammography is also rated ‘Usually Appropriate’ by the ACR. In some specific clinical situations, a clinician might choose to order both ultrasound and diagnostic mammography concurrently, especially if the physical exam is highly suspicious or if the patient is approaching the age of 30. However, as a standalone first step, ultrasound is typically superior due to its effectiveness in dense breast tissue and lack of radiation.

What physical exam features definitively classify a nipple discharge as ‘pathologic’?

Key features that point towards a pathologic cause include: being spontaneous (occurring without squeezing or stimulation), unilateral (coming from only one breast), arising from a single duct, and being persistent. The character of the fluid is also critical; clear (watery), bloody (sanguineous), or serosanguinous discharge is significantly more concerning than milky, green, or brown discharge that is bilateral and from multiple ducts.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026